李佳逊,张方,刘梦娜,董丽
LI Jiaxun,ZHANG Fang,LIU Mengna,Dong Li

• 1:沈阳药科大学工商管理学院
• 2:首都医科大学国家医疗保障研究院

摘要(Abstract)：

目的 整理并总结法国创新药品价格谈判的流程和提交文件的主要内容，归纳其价格谈判的方法和细则，为我国创新药品价格谈判流程优化提供参考。方法 通过法国官方网站公布的法律、法规、官方信息和发布的最新文件，归纳总结法国创新药品谈判流程及价格监管程序。结果 法国创新药品价格谈判机制成熟，评估流程和文件提交要求及内容明确，药品价格变化和监管制度完善。法国创新药品企业完成临床效益评估和药品经济评估后，将报告提供给保健产品委员会进行价格协商和多次价格谈判，以保证评估过程公正，评估结果合理。结论 我国创新药品价格谈判可参考法国建立评审专家利益审查机制，保证谈判过程公平公正；合理设置价格谈判以及价格调控机制，保证谈判结果合理且谈判成果有效落地。
Objective To study the process of French innovative drug price negotiation and the main content of the submitted documents, and to provide reference for optimizing the negotiation process of innovative drugs in China.Methods The laws, regulations, official information and the latest documents published on the French official websites were summarized to investigate the negotiation process and price supervision procedure of innovative drugs in France.Results The negotiation mechanism of French innovative drug price is mature, the evaluation process, document submission requirements and content are clear, and the drug price changes and the regulatory system are perfect.After the French innovative drug enterprises have completed the clinical benefit evaluation and drug economic evaluation, they will provide the reports to the Health Products Committee for price negotiations and to ensure that the evaluation process is fair and the evaluation results are reasonable.Conclusion China′s innovative drug price negotiation can refer to the establishment of the interest review mechanism of expert in France to ensure a fair and just negotiation process.Besides, it is necessary to set up a reasonable price negotiation and price control mechanism to ensure reasonable negotiation results that can be effectively implemented.

关键词(KeyWords)： 法国创新药品;价格谈判;折扣计算;价格监管;临床价值
French innovative drugs;price negotiation;discount calculation;price regulation;clinical value

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李佳逊,张方,刘梦娜,董丽
LI Jiaxun,ZHANG Fang,LIU Mengna,Dong Li

DOI: 10.14066/j.cnki.cn21-1349/r.2021.0620

参考文献(References)：

• [1] National Development and Reform Commision.Circular on issuing opinions on promoting drug price reform(关于印发推进药品价格改革意见的通知)[EB/OL].(2015-05-05)[2020-03-01].https://www.ndrc.gov.cn/xxgk/zcfb/tz/201505/t20150505_963815.html.
• [2] YU X Y,CAI J H,HE C H.Status of China′s Drug Price Negotiation under the Background of Tripartite System Reform[J].Guangxi Medical Journal(广西医学),2019,41(19):2538-2541.
• [3] ZHANG K,CAO S Y,XIONG L P .Status and Negotiated Price in Imported Patent Drug of China[J].Hospital Administration Journal of Chinese People′s Liberation Army(解放军医院管理杂志),2018,25(10):987-992.
• [4] Ministry of Health and Social Affairs.Committee on the Economy of Health Products (Comité économique des produits de santé)[EB/OL].(2012-12-22)[2020-03-05].https://solidarites-sante.gouv.fr/ministere/acteurs/instances-rattachees/article/ceps-comite-economique-des-produits-de-sante.
• [5] Ministry of Health and Social Affairs.The Health Care Products Economic Committee (CEPS) and the Public Declaration of Benefits (DPI) are formed (Composition du Comité économique des produits de santé (CEPS) et déclarations publiques d′intérêts(DPI))[EB/OL].(2009-12-22)[2020-04-06].https://solidarites-sante.gouv.fr/ministere/acteurs/instances-rattachees/article/composition-du-comite-economique-des-produits-de-sante-ceps-et-declarations-316922.
• [6] French National Health Authority.Transparency committee (Commission de la Transparence)[EB/OL].(2020-01-10)[2020-3-25].https://has-sante.fr/jcms/c_412210/fr/commission-de-la-transparence.
• [7] French National Health Authority.Economic and Public Health Assessment Commission (La Commission évaluation économique et de santé publique CEESP)[EB/OL].(2012-11-30)[2021-04-08].https://has-sante.fr/upload/docs/application/pdf/2012-11/br-ochure_imprimablea3rectoverso.pdf.
• [8] French Ministry of Solidarity and Health.Consult the public interest (CONSULTATION DES DéCLARATIONS PUBLIQUES D′INTéRETS)[EB/OL].(2011-12-29)[2020-04-25].https://dpi.sante.gouv.fr/dpi-public-webapp/app/consultation/accueil.
• [9] French National Health Authority.Guidance for national early dialogues on medicinal products(Early dialogue for a medicinal productin clinicaldevelopment)[EB/OL].(2020-04-20)[2020-04-30].https://has-sante.fr/upload/docs/application/pdf/2016-04/early_dialogue_for_a_medicinal_product_in_clinical_development.pdf.
• [10] French National Health Authority.Steps to prepare an economic opinion(étapes d′élaboration d′un avis économique)[EB/OL].(2013-08-30)[2020-04-20].https://has-sante.fr/upload/docs/application/pdf/2013-08/etapes_delaboration_des_avis_defficience.pdf.
• [11] French National Health Authority.Pre-storage meeting with SEESP(Rencontre prédépét avec le SEESP)[EB/OL].(2020-01-18)[2020-03-20].https://has-sante.fr/upload/docs/application/pdf/2020-10/rencontre_pre-depot_avec_le_seesp.pdf.
• [12] Ministry of Health and Social Affairs.A new framework agreement was signed between the Economic Commission on Health Products (CEPS) and the Pharmaceutical Company (LEEM)(Signature d′un nouvel accord-cadre entre le Comité économique des produits de santé (CEPS) et le Les Entreprises du médicament (LEEM))[EB/OL].(2020-03-05)[2020-03-15].https://solidarites-sante.gouv.fr/actualites/presse/communiques-de-presse/article/signature-nouvel-accord-cadre-entre-le-ceps-et-le-leem.
• [13] Legislation.Social security law (Code de la sécurité sociale)[EB/OL].(2019-12-30)[2020-05-01].https://www.legifrance.gouv.fr/codes/texte_lc/LEGITEXT000006073189/.